Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

109.45 -0.47 (-0.43%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options 
Via Benzinga
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
JAZZ Pharmaceuticals (NASDAQ:JAZZ) is an undervalued biopharma stock with strong profitability, reasonable financial health, and steady growth, making it a candidate for value investors. 
Via Chartmill
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients. 
Via Benzinga
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts
Via Benzinga
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors. 
Via Chartmill
Earnings Scheduled For May 6, 2025
Via Benzinga
Preview: Jazz Pharmaceuticals's Earnings
Via Benzinga
A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts
Via Benzinga
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s... 
Via StockStory
Topics World Trade
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Jazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s... 
Via StockStory
Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q1 Results Tomorrow
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results tomorrow after market close. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow afternoon. Here’s what to look for. 
Via StockStory
Despite its impressive fundamentals,JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) remains undervalued.
When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock 
Via Chartmill
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals currently trades at $109.85 per share and has shown little upside over the past six months, posting a small loss of 1.4%. 
Via StockStory
3 Small-Cap Stocks in the Doghouse
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
3 Value Stocks Skating on Thin Ice
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.
JAZZ PHARMACEUTICALS PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:JAZZ showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves. 
Via Benzinga
Topics Earnings
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX
The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility. 
Via Talk Markets
Topics Stocks / Equities
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
Jazz Pharmaceuticals will add dordaviprone, a potential treatment for a rare brain tumor, to its growing oncology pipeline. 
Via Benzinga
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday. 
Via Investor's Business Daily
3 Small-Cap Stocks Skating on Thin Ice
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.